Clinical Trials

Featured Clinical Trials

Yttrium-90 Radioembolization in Combination with Tremelimumab and Durvalumab for Treating Patients with Locally Advanced, Unresectable or Oligo-metastatic Intrahepatic Cholangiocarcinoma Who are Not Candidates for Curative Therapy, RAIDEN Trial

Posted February 11, 2025

This phase I trial tests the safety and side effects of yttrium-90 (Y90) radioembolization combined with immunotherapy drugs tremelimumab and durvalumab in treating patients with intrahepatic cholangiocarcinoma (cancer of the bile ducts in the liver) that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable) who are... Read More »

Submission: State Society or Hem Onc Group webpage – Tagraxofusp AML 0423 clinical trial MED-05227 12/2024

Posted December 27, 2024

A Phase 2 Study of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Untreated CD123+ Acute Myeloid Leukemia (AML) Who Cannot Undergo Intensive Chemotherapy This multicenter open-label phase 2 study will evaluate Tagraxofusp (TAG) in combination with Venetoclax and Azacitidine (Ven/Aza) in adults with previously untreated CD123+ AML who are ineligible for intensive... Read More »

A Phase 3 Study of elacestrant versus standard endocrine therapy in node-positive ER+, HER2- early breast cancer with high risk of recurrence (ELEGANT)

Posted November 22, 2024

Despite advances in the adjuvant treatment of early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, there continues to be a risk of recurrence. The ELEGANT study is a Global, Multicenter, Randomized, Open-label Phase 3 Study with the primary goal to evaluate the efficacy and safety of elacestrant versus standard endocrine... Read More »

Treatment-Naïve CLL: Phase 3 Study of Sonrotoclax Plus Zanubrutinib Compared With Venetoclax Plus Obinutuzumab in Participants With TN Chronic Lymphocytic Leukemia (CELESTIAL)

Posted August 6, 2024

The CELESTIAL study is a multi-center randomized phase III trial to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia. In this study, participants with CLL, without prior treatment will receive either venetoclax plus obinutuzumab combination treatment that is considered a standard first line treatment or receive... Read More »

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)

Posted May 20, 2024

This international, randomized, open-label, Phase 3 study will compare the investigational combination of avutometinib plus defactinib versus Investigator’s Choice of Treatments (ICT) in patients with recurrent LGSOC who have progressed on a prior platinum-based therapy. Avutometinib and defactinib are both a type of drug called a kinase inhibitor. Kinase inhibitors block cancer cell growth. The... Read More »